(Q37566094)

21 August 2017

1 reference

title

Depression and quality of life in psoriasis (English)

1 reference

21 August 2017

1 reference

Abby S Van Voorhees

1

1 reference

PubMed ID

19641281

21 August 2017

Richard Fried

series ordinal

2

1 reference

PubMed ID

19641281

21 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

21 August 2017

Postgraduate Medicine

1 reference

21 August 2017

121

1 reference

21 August 2017

4

1 reference

21 August 2017

154-161

1 reference

The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients.

21 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

An Italian study on psoriasis and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Quality of life issues in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Dimensions of stigmatization in patients with psoriasis in a "Questionnaire on Experience with Skin Complaints'.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

The psychosocial burden of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Role of depression in quality of life for patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Analysis of health care and actual needs of patients with psoriasis: a survey on the Italian population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

The contribution of perceptions of stigmatisation to disability in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Temperament and character profile of patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Relationship between anger and pruritus perception in patients with chronic idiopathic urticaria and psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Divergent beliefs about psoriasis are associated with increased psychological distress

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

21 January 2018

Psoriasis comorbidities

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Atherosclerosis: disease biology affecting the coronary vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Inflammatory aspects of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Perceived stress, stress attributions and psychological distress in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Stress, social support, emotional regulation, and exacerbation of diffuse plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Only limited support for a role of psychosomatic factors in psoriasis. Results from a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

How do personality systems interact in patients with psoriasis, atopic dermatitis and urticaria?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

A randomized trial of etanercept as monotherapy for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2040

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.07.2040

1 reference

21 August 2017

1 reference

PubMed ID

19641281